Purdue Pharma has been granted a patent for a method of treating cancer that involves administering a combination of a glucocorticoid and a specific compound. The patent includes a pharmaceutical composition and a kit designed for this treatment approach. GlobalData’s report on Purdue Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Purdue Pharma, Human telomerase RT biomarker was a key innovation area identified from patents. Purdue Pharma's grant share as of July 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Combination therapy for cancer treatment using glucocorticoids
The granted patent US12064417B2 outlines a method for treating cancer in patients through the administration of a combination therapy that includes a glucocorticoid and a specific compound referred to as formula I, or its pharmaceutically acceptable salts. The claims detail various aspects of this method, including the types of glucocorticoids that can be used, such as dexamethasone, fluocinolone acetonide, and prednisone. The patent also specifies that the combination can be administered concurrently, sequentially, or separately, and provides guidance on the molar ratios of the glucocorticoid to the compound of formula I, ranging from 1:500 to 500:1, with a more specific range of 1:250 to 1:150.
Additionally, the patent identifies specific types of hematologic cancers that can be targeted with this treatment, including multiple myeloma, lymphoma, and various forms of leukemia. It also addresses breast cancer, particularly subtypes such as triple-negative breast cancer and other classifications based on receptor status. The claims further stipulate dosage ranges for both the compound of formula I (10 to 100 mg/kg body weight, with a preferred range of 40 to 80 mg/kg) and the glucocorticoid (0.1 to 1.0 mg/kg body weight). This comprehensive approach aims to enhance the efficacy of cancer treatment by leveraging the synergistic effects of the combined therapeutic agents.
To know more about GlobalData’s detailed insights on Purdue Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
